CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
about
Advances in immunotherapy for pediatric acute myeloid leukemia.CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.Targeting Leukemia Stem Cells in the Bone Marrow Niche.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy
P2860
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
CD33 Splicing Polymorphism Det ...... Oncology Group Trial AAML0531.
@en
CD33 Splicing Polymorphism Det ...... Oncology Group Trial AAML0531.
@nl
type
label
CD33 Splicing Polymorphism Det ...... Oncology Group Trial AAML0531.
@en
CD33 Splicing Polymorphism Det ...... Oncology Group Trial AAML0531.
@nl
prefLabel
CD33 Splicing Polymorphism Det ...... Oncology Group Trial AAML0531.
@en
CD33 Splicing Polymorphism Det ...... Oncology Group Trial AAML0531.
@nl
P2093
P2860
P356
P1476
CD33 Splicing Polymorphism Det ...... Oncology Group Trial AAML0531.
@en
P2093
Alan S Gamis
Betsy A Hirsch
Irwin D Bernstein
Jatinder K Lamba
Jessica A Pollard
Lata Chauhan
Michael R Loken
Miyoung Shin
Rhonda E Ries
Richard Aplenc
P2860
P304
P356
10.1200/JCO.2016.71.2513
P407
P577
2017-06-23T00:00:00Z